Novogen licenses phase 2 - ready molecule GDC-0084 (Swings & Roundabouts ep. 033)

Friday, March 10, 2017 2:30 AM +00:00

Novogen licenses phase 2 - ready molecule GDC...0:0019:23
LIVEQuality1  AudioSubtitleDownloadSpeed1  
SWINGS & ROUNDABOUTS
NOVOGEN LIMITED
Dr James Garner

In late 2016, Novogen announced that it had in-licensed a drug from Genentech, a subsidiary of Roche. The drug, a small molecule phosphoinositide-3-kinase (PI3K) inhibitor, called GDC-0084, targets Glioblastoma Multiforme (GBM), the most common form of primary brain cancer, two thirds of whom are largely unresponsive to existing pharmaceutical treatments.


Leave a Comment

Your email address will not be published

WEBCAST Calendar

  • 16 Mar

    02:00

    Working Together During Coronavirus Outbreak

    CISCO SYSTEMS
  • 16 Mar

    02:00

    FYI Resources DFS highlights low capital and operating costs for kaolin and HPA project

    FYI RESOURCES LIMITED
  • 16 Mar

    02:00

    Eli Lilly CEO talks partnering with AbCellera Biologics to co-develop a coronavirus cure 14.03.2020

    ELI LILLY AND COMPANY
  • 16 Mar

    02:00

    amaysim Australia Ltd (AYS) CEO & Managing Director, Peter O’Connell 11.03.2020

    AMAYSIM AUSTRALIA LIMITED
  • 16 Mar

    02:00

    2021 Ford Mustang Mach-E: Winter Testing All-Wheel Drive | Ford 13.03.2020

    FORD MOTOR COMPANY